# Insight Molecular Diagnostics Inc. (IMDX) · Edgar & Edgarette company card

> Insight Molecular Diagnostics (IMDX) grew revenue 116% in FY2025 to $4 million, operating margin -1261% against a -4.3% median for in vitro & in vivo diagnostic substances, equity -122% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1642380 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/IMDX) · [JSON](https://www.pops4.com/boards/company/IMDX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $4M |
| Revenue growth, 1 year | 115.6% |
| Revenue growth per year | 16.5% |
| Operating margin | -1260.8% (prior year -3245.1%) |
| Net margin | -1238.5% |
| Operating cash flow | −$22M |
| Capital spending | $3M |
| Free cash flow | −$25M |
| Cash | $12M |
| Long-term debt | — |
| Total assets | $26M |
| Total equity | −$31M |
| Equity ÷ assets | -122.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -63.82 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -8.02 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -1260.8% in FY2025; revenue is hard to predict: its 80% range is ±76%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $4.1M (FY2025). Experience: revenue up 115.6% on the year, up 16.5% a year over 4 years; operating margin -1260.8%, up from -3245.1%. Soundness: equity -122.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.8M and $20.7M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.4M to $23.9M. A statistical range, not company guidance. Against peers (161 filers, $50M+ revenue, its industry group): operating margin -1260.8% against a -4.3% median; growth 115.6% against 12.6%.

Range logged 2026-09-26, receipt 0c3e5a23bc5e9e01, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-06-17 ([filing](https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/0001493152-26-029078-index.htm))

## Recent filings

- 8-K · filed 2026-09-21 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1642380/000149315226043560/0001493152-26-043560-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1642380/000164238026000011/0001642380-26-000011-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1642380/000149315226036863/0001493152-26-036863-index.htm)
- 8-K · filed 2026-06-17 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1642380/000149315226029078/0001493152-26-029078-index.htm)
- 10-Q · filed 2026-05-13 · [filing](https://www.sec.gov/Archives/edgar/data/1642380/000164238026000008/0001642380-26-000008-index.htm)
- 8-K · filed 2026-05-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1642380/000149315226022721/0001493152-26-022721-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001642380.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1642380

## Cite

POPS4, Edgar & Edgarette: Insight Molecular Diagnostics Inc. (IMDX) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/IMDX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.